ABIONYX Pharma SA (609.SG)
| Previous Close | 1.0020 |
| Open | 0.9980 |
| Bid | 0.9950 x 25000 |
| Ask | 1.0840 x 25000 |
| Day's Range | 0.9950 - 0.9980 |
| 52 Week Range | 0.8780 - 1.9060 |
| Volume | |
| Avg. Volume | 164 |
| Market Cap | 33.58M |
| Beta (5Y Monthly) | -0.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings Date | Mar 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, May 07, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):
Business WireABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
TOULOUSE, France & LAKELAND, Mich., May 02, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2023, dated April 30, 2024.
Business WireABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
